Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule

Key Points

• Ebola is a rare but deadly disease caused by a filovirus for which no treatment or vaccine is available. Vaccine development for such diseases is hampered by the inability to test vaccines in volunteers or a target population.

• The Food and Drug Administration (FDA) has instituted the 'animal rule' to allow approval of vaccines and drugs that cannot be tested in humans based on immune correlates in animal models.

• In the case of Ebola, the relevant animal models are non-human primates and mice.

• For Ebola, immune correlates consist of immunoglobulin G responses, although other factors, such as T cells, are also likely to be important in a successful immune response.

• Vaccine candidates for Ebola vaccine include the glycoprotein and nucleocapsid proteins.

• Initial testing of Ebola vaccines has shown a protective effect in non-human primates and positive antibody titres in humans.

For diseases that are both rare and lethal, it is difficult to test vaccines. Sullivan and colleagues describe the use of immune correlates and the animal rule for the licensing of Ebola vaccines.

Abstract

Ebola virus infection is a highly lethal disease for which there are no effective therapeutic or preventive treatments. Several vaccines have provided immune protection in laboratory animals, but because outbreaks occur unpredictably and sporadically, vaccine efficacy cannot be proven in human trials, which is required for traditional regulatory approval. The Food and Drug Administration has introduced the 'animal rule', to allow laboratory animal data to be used to show efficacy when human trials are not logistically feasible. In this Review, we describe immune correlates of vaccine protection against Ebola virus in animals. This research provides a basis for bridging the gap from basic research to human vaccine responses in support of the licensing of vaccines through the animal rule.

Main

The filoviruses, Ebola virus and Marburg virus, cause outbreaks of highly lethal haemorrhagic fever. Filovirus mortality rates average greater than 50%, and the highest recorded mortality rates have been for Ebola Zaire virus (88%) and Marburg Angola virus (90%)¹. After infection, these haemorrhagic fever viruses induce a sustained high fever followed by aberrant coagulation and vascular permeability, which causes bleeding, bruising and a rash. After the asymptomatic incubation period, which can last days to weeks, symptoms of a typical viral infection emerge; headache, nausea, fever and malaise precede more serious haemorrhagic symptoms and, in fatal cases, death results from multi-organ failure owing to shock. The treatments for filovirus infection are palliative, and consist primarily of supportive care, including hydration and pain management.

Most filovirus outbreaks have occurred in equatorial Africa, ranging from the Ivory Coast in the west, to Uganda in the east, occasional Marburg virus in Kenya and as far south as Angola, but are concentrated in Central Africa, particularly the Democratic Republic of the Congo, the Republic of the Congo and Uganda. In most outbreaks, epidemiological investigation has linked the index human case to animal contact, either non-human primate or antelope, or travel into mines and presumed exposure to bats¹. Bats have recently been identified as a possible natural reservoir for filoviruses after the recovery of three Marburg virus isolates from bats². Transmission between humans generally requires close contact with blood or body fluids during care for the ill and burial practices that include bathing the deceased. Outbreak control is facilitated by patient isolation, the use of protective equipment and avoidance of contaminated needles. Public health responses are directed toward surveillance, diagnosis and community education.

There is no effective treatment or cure; therefore, vaccine development is crucially important as a strategy for minimizing the public health, societal and economic impacts of natural filovirus outbreaks. However, vaccine efficacy testing for Ebola virus is difficult: there is no readily identifiable high-risk population that can be targeted for a placebo-controlled clinical efficacy trial because outbreaks are unpredictable and sporadic, both geographically and temporally.

Regulatory approval of vaccines

The pathway to a vaccine licence includes an assessment of toxicity, immune response and efficacy in pre-clinical animal studies, clinical safety studies (Phase I and II) and clinical efficacy studies (Phase III) (Table 1). Clinical efficacy studies usually evaluate incidence rates in vaccinated individuals compared with placebo recipients, and are typically performed in populations that are known to be at risk for a particular condition and in a setting where the known incidence has been defined, to allow study design and assess feasibility.

Table 1.

Traditional approach to evaluation of candidate vaccines in clinical trials

Phase of vaccine clinical trial	Objectives of the trial	Subject number	Typical duration
Phase I	Safety, tolerability, dose ranging and evidence of immunogenicity	20–80	1–2 years
Phase II	Safety, dose optimization and immunogenicity as signals of potential efficacy	100–300	2+ years
Phase IIb	Proof of concept trial (evidence of efficacy and safety); can be used to determine which candidates advance to Phase III	1,000–5,000+	2+ years
Phase III	Large placebo-controlled trial for efficacy and safety, with intention to collect data for licensing	2,000–5,000+	4+ years
Phase IV	Post-licensing; further definition of risks, benefits and optimal use	Variable	Variable
*From ClinicalTrials.gov and the National Institute of Allergy and Infectious Diseases (Understanding Vaccine Clinical Studies) (see Further information).

Vaccines are licensed based on a risk–benefit analysis of the candidate vaccine safety profile, efficacy observed in Phase III clinical trials and public health need. In some cases, a known correlate of human protection defined for a particular pathogen by earlier Phase III trials can be used to predict efficacy and support licensing for subsequent vaccine formulations. Because of its sporadic nature, the incidence of Ebola virus infection in selected human populations is not predictable and does not allow for adequate statistical powering of a Phase III efficacy trial. Moreover, immune correlates of protection from disease in humans remain unknown and therefore cannot be used to assess candidate vaccine efficacy. To facilitate the licensing of drugs and biologics when efficacy cannot be evaluated in the setting of natural infection, the US Food and Drug Administration (FDA) promulgated a new regulation in 2002 as an alternative licensing pathway for pharmaceutical products that target highly lethal pathogens. The FDA's 'animal rule' allows for approval based on animal efficacy data conducted under Good Laboratory Practice controls, and human safety and immunogenicity data conducted under Good Clinical Practice controls, that support the correlate of protection defined in the animal model (described in the FDA Code of Federal Regulations CFR 21 314.600; see Further information). The animal rule is intended to be used as a pathway for regulatory review only when there is no other way to licence a vaccine³.

The animal rule for vaccine licensing

Application of the animal rule to a vaccine for Ebola virus is reasonable, and is probably the only way to develop a filovirus vaccine for human use, although the additional complexity of performing Good Laboratory Practice experiments under biosafety level 4 containment will be challenging. This approach requires an understanding of pathophysiology and immune protection in the animal species used to predict human efficacy. The end point in an animal efficacy study must correlate with the desired effect in humans, which is typically a survival benefit or attenuation of severe disease, and allow determination of an effective dose-response relationship in animals and humans. FDA regulatory review and approval will require data substantiating that the vaccine under consideration is reasonably likely to provide a benefit in humans. In the case of therapeutic drugs, animal model data presented to substantiate a predicted therapeutic benefit must demonstrate effects at the biochemical level through elucidation of the mechanism of pathogen toxicity. For example, implementation of the animal rule to license pyridostigmine bromide in 2003 for the pre-treatment of Soman nerve gas exposure was based on data from rhesus macaques because Soman pathophysiology is well characterized in this species³ (see Further information for a link to Drug Information from the Centre for Drug Evaluation and Research). In rhesus macaques, Soman irreversibly blocks acetylcholinesterase, an enzyme necessary for proper neurotransmission; data to support the licensing of pyridostigmine bromide provided evidence that it is a competitive and reversible blocker of Soman that binds its target enzyme.

Unlike pharmacological therapeutics, vaccines are not designed to block molecular targets, but instead, interrupt the pathogen replication cycle by preventing infection or clearing virus-infected cells through natural host defence mechanisms that constitute protective immunity. Licensing through the animal rule requires data showing that markers or correlates of protective vaccine-induced immunity are predictive for survival in an exposed host. Identification of immune correlates in animals has not been a requirement for FDA approval of human vaccines and, to date, no vaccines have been licensed under the animal rule. This paradigm therefore presents a challenge for basic, translational and clinical scientists to identify one or more parameters of primary immunity in animals that predict immunological protection against infection and can be tested in human clinical trials.

Immune correlates of vaccine protection

Immune correlates of protection vary depending on the mode of vaccination, the route of infection and the nature of the immunological measurement. An immune assessment associated with disease outcome does not specify a mechanistic relationship between the immune marker and protection. Immunological correlates associated with efficacy vary in the strength of the quantitative and predictive relationship between a specific immune response and disease outcome^4,5,6. For the purpose of this Review, we use the definition of a correlate provided in the scholarly review by Plotkin⁴: a “specific immune response to a vaccine that is closely [associated with] protection against infection, disease, or other defined endpoint.” Given the multifactorial nature of immunological protection, the most reliable correlate of immunity is also a determinant of protection, and reflects the underlying immune mechanisms responsible for resistance to infection. However, the correlate may be associated with protection without being causally related to virus clearance. The strength of the correlation required to support the licensing of an Ebola vaccine is not specified in the animal rule, but is balanced against pathogen lethality, the risks of infection, the complexity of the immune responses that mediate protection and the urgency of the public health need.

Ebola virus outbreaks are unpredictable and survival is low, so it has not been possible to define human correlates of immunity to natural infection. Retrospective studies in the rare subjects who clear Ebola virus infection have identified qualitative associations between immune end points and survival^{7,8,9,10,11,12,13,14,15,16}, but such studies have not identified predictive markers or surrogates of protective immunity. For the purposes of Ebola vaccine development, immune correlates of survival can only be established when the pathophysiology of an animal model closely resembles that of human disease. The selection of immunological end points for correlate assessment is informed by knowledge of the underlying mechanism of protection, a subject that remains under investigation for Ebola virus. The potential immune effectors involved in virus clearance may be dependent on one arm of the immune system (for example, cellular or humoral immunity). Alternatively, they may be dependent on various components of the innate and adaptive immune response. Determination of immune correlates of protection must therefore evaluate a range of phenotypic and functional markers of immunity (Fig. 1). T cell phenotype can be assessed with precision on a single-cell level by exploiting markers of lineage, homing profile and memory phenotype, such as CD4, CCR7 and CD28, respectively, among others. Such phenotypes can be defined further by their functional profiles (for example, those that relate to T helper function or surface markers associated with central T cell memory, T cell effector memory and T cell terminal effector phenotypes). Similarly, B cell immunological end points are captured using phenotypic markers, including CD20 expression and immunoglobulin (Ig) class, and functional assays that measure in vitro effector characteristics, such as direct virus neutralization or antibody-dependent cellular cytotoxicity.

Figure 1. Determination of immunological end points that correlate with vaccine efficacy.

Standard assays for the determination of immune markers include those that measure humoral immunity, such as in vitro virus neutralization, ELISA (enzyme-linked immunosorbent assay) and EIA (enzyme immunoassay) (a), and others that measure cell-mediated responses, including antigen-stimulated proliferation or cytolytic activity. Correlates can also be sought in additional phenotypic (b) and functional immune markers (c) that associate with vaccine efficacy. T cell lineage markers, cytokine secretion, antibody class and effector functions can individually, or in combination, segregate with host survival outcome. Grz, granzyme; IFN, interferon; Ig, immunoglobulin; IL, interleukin; NK, natural killer; T_CM, T cell memory; T_E, T cell terminal effector; T_EM, T cell effector memory; T_H, T helper; TNF, tumour necrosis factor.

Correlates of vaccine efficacy can be affected by variables such as the structure or stability of a specific immunogen, but can also be influenced by the mode of antigen delivery and processing in the host. Therefore, selection of immune end points is focused initially on mediators that are relevant to the vaccine platform. For example, protein formulations are often processed through endocytic pathways that stimulate CD4⁺ T helper 2 (T_H2) cell responses and promote antibody production. By contrast, gene-based vaccines allow synthesis of foreign proteins within cells, which leads to processing of antigens through the proteasome, a process that more effectively elicits CD8⁺ T cell responses, while also eliciting antibody responses. Some gene-based vaccines have the potential to generate broad responses because of their ability to target antigen-presenting cells (APCs) directly, which is a property of certain viral vectors. The quality and range of vaccine-induced immune responses can therefore be influenced by the specificity of viral vectors for different APC targets, and must be determined empirically in animal models of vaccine protection for which immune reagents and assays are available.

Animal models of Ebola virus infection

Protective immunity and immune correlates against Ebola virus infection have been best defined in mice, owing to the availability of inbred strains, which has allowed the quantitation of vaccine-induced humoral and cellular responses. A guinea pig infectious challenge model has also allowed us to define immune correlates in a rodent model that shares closely related coagulation defects with those observed in primates¹⁷. Xu and colleagues¹⁸ used plasmid DNA vectors that encode sequences for the Ebola virus envelope glycoprotein, GP, expressed on the surface of virions and virus-infected cells, and NP, the viral nucleocapsid protein that forms organized lattices when synthesized intracellularly^19,20,21. Intramuscular vaccination with GP vectors generated potent CD8⁺ cytolytic responses 6 weeks after the first immunization in mice. Both GP and NP vectors induced high titre antigen-specific IgG antibodies that were present before infectious challenge and correlated with survival in guinea pigs. Although antibody levels provided a quantitative marker of immune protection, passive transfer of hyperimmune sera from these animals did not protect naive recipients. Similarly, a role for Ebola virus IgG as a correlate of vaccine protection was observed after mouse or guinea pig immunization with Venezuelan equine encephalitis GP and NP vaccines^22,23. These results suggested that IgG did not completely block infection, required cofactors that were not present in the serum or lacked appropriate effector functions that were dependent on affinity or epitope specificity²⁴. In support of the last possibility, other monoclonal antibodies or polyclonal Ig from survivors of active infection in either humans or mice showed success in protecting naive mice from disease and death^25,26, confirming that Ebola virus-directed antibody quality is variable and is influenced by the way in which it was generated.

Evidence from rodent models of Ebola virus infection suggested that vaccine-induced IgG against Ebola virus GP is a quantitative immune end point that reflects the magnitude of underlying combined B and T cell vaccine responses. It is likely that cellular responses are present after immunization, but currently available methods for assessing these end points lack the sensitivity or specificity for reliable detection. Indeed, a necessary role for CD4⁺ and CD8⁺ T cell functions is unambiguous from genetic knockout and adoptive transfer studies in mice in which these components have been specifically targeted for deletion or enhancement, respectively^27,28,29. Likewise, natural killer cells also seem to functionally complement vaccine-induced Ebola virus antibodies for virus clearance in mice³⁰.

Immune correlates of vaccine protection

The murine model of Ebola virus infection has revealed pathways and mechanisms of immune protection that are unparalleled in other animal models. However, vaccine approval for human use requires the use of a species that reliably reflects human disease, such as a non-human primate. A number of aspects of the Ebola virus–host interaction differ between murine and human infections; for example, to infect mice, virus isolates that infect humans must be adapted by serial passage. In this regard, Ebola virus infection in non-human primates more closely mimics disease pathogenesis observed in humans. Therefore, immune correlates of vaccine protection must be defined in non-human primates despite the relative paucity of reagents that are available for discerning and manipulating primate mediators of immune protection. Discordant results of vaccine efficacy studies between mice and non-human primates have been observed with Ebola vaccines. The importance of ELISA (enzyme-linked immunosorbent assay) IgG as an immunological end point established by DNA vaccination in mice guided investigators to augment genetic vaccine strategies with viral vectors that were capable of eliciting higher-magnitude antibody responses in primates than was possible with plasmid DNA alone. Alternative vector combinations were screened in mice to identify the regimen that yielded the highest ELISA IgG titres against Ebola virus GP (Table 2). Successful immune protection of non-human primates was accomplished using a heterologous prime–boost vaccine with DNA and replication-defective recombinant adenovirus (rAd) vectors encoding Ebola virus GP and NP³¹, the platform that shows the highest potency for eliciting antigen-specific antibodies. The first studies that used the DNA–rAd vaccine in non-human primates efficiently induced high-titre antibodies and CD4⁺ T cells before infectious challenge. Subsequent assessment of a single-shot rAd Ebola vaccine (omitting the DNA priming step) confirmed the presence of antigen-specific ELISA IgG in survivors and demonstrated the reproducibility of the antibody response as a correlate of protection. Furthermore, other Ebola vaccines developed for macaques based on vesicular stomatitis virus³², parainfluenza virus³³ or virus-like particles (VLPs)³⁴ have since reported that protective immunity correlated with the presence of virus-specific antibodies in all vaccinated survivors of infectious challenge. The efficacy of these additional vaccines in non-human primates clearly establishes that protective immunity to Ebola virus infection can be achieved and offers the opportunity for further detection of immune correlates. Whether immune correlates of protection will apply across vaccine platforms remains unknown and may depend on whether these different vaccine vectors elicit related pathways of immunity to confer protection against challenge, but it is noteworthy that each of the vaccines shown to be 100% effective for protection of non-human primates induced antibody responses (Table 3).

Table 2.

Immune correlates as a basis to optimize vaccine strategies

Vaccine		EliSA IgG titre*
Prime	Boost	Mouse	Macaque
DNA	rAd	200,000	75,000
rAd	rAd	100,000	Not determined
rAd	None	16,000	Not determined
DNA	DNA	12,000	Not determined
DNA	None	6,400	2,000
*End point antibody titres were measured in sera from mice immunized with different combinations of DNA and recombinant adenovirus (rAd) vectors encoding Ebola virus proteins, and used to prioritize candidate vaccines for testing in cynomolgus macaques. ELISA, enzyme-linked immunosorbent assay; Ig, immunoglobulin.

Table 3.

Vaccines inducing uniform protective immunity in non-human primates

Approach	Virus*	Antigen†	Immunity§		Refs
			Humoral	Cellular
Whole virus or subunit
Virus-like particle	Ebola virus	GP+VP40+NP	IgG	(CD4 or CD8)	34
Gene-based
Adenovirus	Ebola virus and Marburg virus	GP	IgG	(CD8)	44,45
DNA	Marburg virus	GP	IgG	CD4 and (CD8)	N.J.S., unpublished observations
DNA or adenovirus	Ebola virus and Marburg virus	GP+NP	IgG	CD4	31
Parainfluenza	Ebola virus	GP and GP+NP	IgA	(CD4)	33
Venezuelan equine encephalitis virus	Marburg virus	GP and GP+NP	IgG	Unknown	43
Vesicular stomatitis virus	Ebola virus and Marburg virus	GP	IgG	Unknown	32
*Immunization strategies that have yielded 100% protection in non-human primates are shown along with the challenge virus, Ebola virus or Marburg virus.
†Vaccines contained protein or coding sequences for the different virus antigens; glycoprotein (GP) was included in all successful strategies.
§Pre-challenge cellular immune responses were observed sporadically (parentheses indicate partial responses), but ELISA (enzyme-linked immunosorbent assay) immunoglobulin G (IgG) was a consistent indicator of vaccine-induced protective immunity. NP, nucleoprotein,

The efficacy of non-human primate vaccines has been most consistently associated with the presence of ELISA IgG before infectious challenge. Because the pathophysiology and clinical symptoms of non-human primate Ebola virus infection accurately recapitulates human Ebola virus infection³⁵, this observation provides an important lead in the development of Ebola vaccines for human use. This animal model therefore satisfies the requirements for vaccine licensing using the animal rule. However, as stated at the beginning of this Review, vaccine regulatory review will be facilitated by quantitative measurements of immunity that predict protection from infection. As a rigorous test for the strength of ELISA IgG as a correlate of immune protection, the predictive value of IgG titres was evaluated using sera from non-human primate subjects immunized with rAd5-based Ebola vaccines that encoded various combinations of GP and NP, as well as different mutated versions of GP. Nearly complete survival can be predicted in subjects that generate a particular pre-challenge titre of ELISA IgG against GP (Fig. 2). Most licensed vaccines have not demonstrated 100% protective efficacy before FDA approval, so identification of a precise Ebola virus IgG threshold titre will be dependent on the level of vaccine efficacy specified. A survival rate of 85% (Fig. 3) establishes a lower threshold for the immune correlate of protection (Fig. 2). Requirements for vaccine efficacy will probably be balanced against risks for mortality in different exposure situations.

Figure 2. Assessment of antigen-specific immunoglobulin G (IgG) as a correlate of Ebola vaccine efficacy.

Immune sera from macaques immunized with genetic vaccines encoding wild-type or mutant Ebola virus glycoprotein alone or in combination with nucleoprotein showed a spectrum of IgG antibody titres measured by ELISA (enzyme-linked immunosorbent assay). Antibody titre was a quantitative predictor (surrogate) for vaccine efficacy; 100% immune protection was predicted by an antibody titre of 1:3,700.

Figure 3. Ebola vaccine development pathway using the animal rule.

Early vaccine candidates are optimized for immune potency in small animal models. Selected candidates are evaluated further in an animal model that adequately represents infection in humans (cynomolgus macaques) to establish an immune correlate of vaccine efficacy, and a pivotal animal study is performed to bridge the immune correlate between macaque efficacy studies and human Phase II clinical trials. Data from Phase III animal studies and expanded Phase II human studies are compiled for regulatory review and vaccine licensing.

ELISA IgG serves as a useful example of an immune correlate of protection in cynomolgus macaques after immunization with rAd5 vaccines. However, it may not be the definitive correlate that bridges the gap between animal and human immune responses for vaccine licensing. The question remains of whether additional correlates can increase the value of ELISA IgG to predict protective immunity against Ebola virus. Those subjects that mount quantitatively similar antibody titres but exhibit different survival outcomes offer an opportunity to explore functional attributes of antibodies that may enhance the distinction between survivors and fatalities based on antibody quality. Although direct in vitro virus neutralization assays are not predictive for protection in non-human primates, this effector function has occasionally been reported in samples from Ebola vaccine-immunized macaques³². More recently, antibody-dependent cellular cytotoxicity was detected after vaccination with VLPs³⁴. Neither of these effector functions was a quantitative correlate of protective immunity. However, the data imply that ELISA IgG titres may indeed reflect the activity of underlying immunological components.

In addition to the role for T cells in antibody effector function, the mechanism by which the immune system confers protection is also likely to involve T cells. Although ELISA IgG is a quantitative and reliable correlate for vaccine efficacy, and immune protection can be transferred from immune serum to naive rodents, passive transfer failed to protect non-human primates, suggesting that the mechanism of immune protection against Ebola virus infection in primates is more complex than in rodents^26,36 (N.J.S., unpublished observations). Furthermore, mouse adoptive transfer and knockout studies that implicated both B and T cell mediators of protective immunity suggest that the mechanism of vaccine-generated Ebola virus immunity is probably multifaceted, even in mice. The mechanism of protection in primates might be similarly complex. Indeed, preliminary immunodepletion studies of T cell subsets in macaques suggest that cellular immunity is required for virus clearance (N.J.S., unpublished observations). Such mechanistic studies do not necessarily translate to the identification of pre-challenge correlates of immunity, but the immune correlate of protection is probably related to underlying mechanisms of virus clearance. For example, if cytotoxic T lymphocytes (CTLs) are required, the observed correlation between survival and vaccine-induced antibody titres may simply reflect CD4⁺ T cell activation that simultaneously provides B cell co-stimulation and helper functions needed for CTL activation. The absence of neutralizing activity associated with the IgG correlate suggests that antibodies do not contribute directly to clearance of virus-infected cells in the host.

Despite the mechanistic evidence for cellular immunity in vaccine-induced immune protection in animal models of Ebola virus infection, CD4⁺ and CD8⁺ T cell responses are either low (near the assay limits of detection) or inconsistently observed. However, there is a strong possibility that traditional assays lack the sensitivity needed to detect the relevant determinants of cell-mediated immunity. Vaccine-induced cellular responses have traditionally been assessed by measuring the level of antigen-inducible effector functions, such as proliferation, cytolytic killing or cytokine secretion from specific T lymphocyte lineages after ex vivo stimulation with relevant antigens. These methods require extended in vitro culture, which is somewhat artificial and may not capture comprehensive T cell potential, especially in memory populations that do not display typical effector functions. Newer, more-sensitive methods for analysis of cellular immunity offer promise for more-detailed assessment of T cell phenotype and function (Fig. 1). Furthermore, advanced approaches for evaluating complex information from polychromatic flow cytometry T cell assays open new possibilities that will be useful for elucidating additional immune correlates^37,38,39. If additional, relevant immunological end points are revealed by such analyses, they may prove to be beneficial complements to ELISA IgG for prediction of vaccine efficacy. To achieve a determinant of immunity for filoviruses, we may need to measure a combination of specific immunological functions that include both antibody and cellular responses. For filoviruses and other viruses, such as HIV-1, herpes simplex virus and hepatitis C virus, this may require discovery of new approaches for measuring cellular immunity, and as the complexity of protective immunity increases it is less likely that the measurements will translate accurately from animal models to humans. Therefore, the immediate goal in filovirus vaccine development is to define a reliable correlate that can be used to support licensing of a vaccine based on the animal rule. Ultimately, the strength of an antibody or T cell correlate will have to be confirmed in human clinical trials, using the final candidate vaccine in a comparative analysis of non-human primate and human immune responses.

Immune correlates of Ebola vaccine immunity in non-human primates provide a basis for evaluating a vaccine that protects against lethal challenge for its immunogenicity in humans. Although further confirmation could theoretically be derived from survivors of natural Ebola virus infection, such subjects are rare and the time from recovery is variable. After the first outbreak of Ebola virus, the total survivor cohort constituted only 12% of identified cases. Therefore, analyses of human immune responses have been performed only retrospectively, at variable times and in small numbers of subjects. It is noteworthy that the presence of Ebola virus-specific ELISA IgG has been associated with survival from natural infection⁷. Additional immunological markers that segregate with human survival from natural infection include specific human leukocyte antigen, class B alleles¹⁵ and T cell activation as assessed by cytokine production^12,13, but these correlative parameters are observational, and therefore fall short of defining predictive indicators of protective immunity. In addition, it is not possible to discern whether the surveyed immunological end points reflect mediators of protection or are simply memory responses generated by exposure to virus.

Ultimately, the licensing of vaccines for human use will require bridging of the immune correlate between pivotal animal efficacy studies and placebo-controlled clinical trials in human volunteers (Fig. 3). To this end, a Phase I randomized human clinical trial has been completed for an Ebola DNA vaccine. The first Ebola vaccine clinical trial showed that all 20 of the vaccinated individuals who were immunized with three doses generated positive antibody titres as measured by ELISA against GP or NP, and antibody was present in all individuals regardless of vaccine dose, which ranged from 2 to 8 mg of DNA⁴⁰. The range of antibody titres was similar to those observed in non-human primates that were vaccinated with a similar regimen³¹, indicating that the monkey model is a valid predictor of human immune responses against Ebola virus antigens.

Ebola vaccines have demonstrated antigen-specific protective immunity against infection in monkeys, and efficacy correlates quantitatively with GP-specific ELISA IgG titres. Antigen-specific T cell responses are also elicited by these vaccines, particularly after DNA prime–rAd boost immunization, and probably contribute to virus clearance and immune protection, although the mechanism of protection in primates has not been fully defined. Because the pathophysiology of rodent infection differs from that of human and non-human primates, immune mechanisms and correlates of protection are most reliably determined in non-human primate infectious challenge studies. The development of more-sensitive and specific T cell immune assays in non-human primates could further aid the effort to define immunological end points that are relevant for vaccine licensing. Gene knockouts that target specific immune functions in non-human primates have not yet been perfected, but immunodepletion with reagents specific for discrete immune cell subsets will help elucidate immune protective mechanisms against Ebola virus, as has been done for other pathogens, such as smallpox and HIV-1 (Ref 41, 42). Such studies will strengthen confidence in present or future immune correlates that predict Ebola vaccine efficacy in humans.

Application of the animal rule to other diseases

Vaccine licensing using the animal rule will be applicable to a number of pathogens for which traditional clinical efficacy trials are not possible. Such diseases include those caused by highly pathogenic agents that are precluded from human testing because direct challenge would require exposing healthy human volunteers to a lethal substance or because populations that are at risk for natural infection cannot be identified for efficacy trials. The Centers for Disease Control proposed a list of category Apriority pathogens, which would include viral agents, such as Ebola virus, Marburg virus and smallpox viruses, as well as bacterial agents, such as those that cause plague, botulism and anthrax. Although some of these agents do not pose an immediate public health concern in the United States, the animal rule is intended to provide a pathway for licensing of vaccines for use worldwide and against highly transmissible agents that could be used as bioweapons. In this way, vaccines or therapeutic interventions could be licensed in advance of a threat and stockpiled for use in an emergency. In addition, the rule would also prove useful for natural infections that are episodic and unpredictable in nature, such as West Nile virus, avian influenza or SARS (severe acute respiratory syndrome). Such diseases threaten public health episodically, but have not yet become established in a sufficiently large population to allow clinical efficacy studies.

Concluding remarks

To date, no vaccines have received regulatory approval and been licensed using the FDA animal rule. Here, we have provided a framework for understanding this regulatory pathway and how studies of vaccine-induced protective immune responses in animals might provide support for licensing. This pathway does not diminish the level of regulatory review required for vaccine approval; extensive human testing is still required to demonstrate safety and immunogenicity. Furthermore, the data in support of licensing may actually exceed the requirements of the traditional approval process, as an immune correlate of vaccine protection must also be revealed, which is not required for currently used licensed US vaccines. The predictive relationship between animals and humans for protective efficacy is unknown, and therefore an immune correlate is used to bridge the gap between animal efficacy studies and human immunogenicity trials. It has not yet been determined what level of efficacy in animals will be required for vaccine approval, but vaccines currently administered to the US population have provided efficacies in human trials that are as low as 18%. Higher potency may be required for vaccines approved using the animal rule because of the expectations that they would be highly effective and useful in an emergency, but even this level of efficacy will provide a substantial benefit against pathogens with high mortality and therefore may be an acceptable level for countermeasures against emerging natural infections or deliberate biodefence threats.

Glossary

Immune correlate

A specific immune response to a vaccine that is closely associated with protection against infection, disease or some other defined end point.

Good Laboratory Practice

A set of principles that provides a framework within which laboratory studies are planned, performed, monitored, recorded, reported and archived.

Good Clinical Practice

An ethical and scientific quality standard for designing, conducting, recording and reporting trials that involves the participation of humans.

Biographies

Nancy J. Sullivan is Chief of the Biodefense Research Section at the National Institutes of Health (NIH) Vaccine Research Center (VRC), Maryland, USA. As a doctoral student at Harvard, Massachusetts, USA, she studied molecular interactions of HIV envelope glycoproteins with host cells and antibodies. She began her postdoctoral work studying filoviruses at the University of Michigan, USA, and continued her fellowship with Gary Nabel at NIH when he was selected as Director of the VRC. She became an independent investigator in 2006. Her laboratory focuses on the molecular mechanisms of virus–host interactions, viral immunology and preclinical development vaccines in non-human primates, with primary interest in filoviruses and other emerging infectious agents. She has a special interest in understanding how Ebola and Marburg viruses circumvent host immune responses to establish initial infection, and defining elements of host immunity that are essential for virus clearance. These basic research pursuits inform preclinical primate studies aimed at developing effective vaccines against emerging pathogens.

Julie E. Martin is Deputy Chief of the Clinical Trials Core (CTC) of the Vaccine Research Center (VRC), Maryland, USA. She is Principal Investigator for Phase I protocols to study the safety and immunogenicity of vaccines for biodefence and emerging infectious diseases and Associate Investigator for Phase I HIV vaccine clinical trials at the VRC. She joined the National Institute of Allergy and Infectious Diseases in 2002 as a clinical fellow in allergy and immunology. In 2003, while completing her fellowship, she began working with Barney Graham in the Viral Pathogenesis Laboratory and Clinical Trials Core at the Vaccine Research Center. There, she conducted basic research studying a mouse model of antigen presentation, while assisting with vaccine clinical trials design, implementation and data analysis. In 2006, she began in her role as Staff Physician and Principal Investigator in the CTC. She is board certified in allergy and immunology by the American Board of Allergy and Immunology and board certified in internal medicine by the American Board of Internal Medicine. She graduated from Oklahoma State University Center for Health Sciences, College of Osteopathic Medicine in 1998 and she completed her residency in internal medicine at Johns Hopkins Bayview Medical Center in Baltimore, Maryland, in 2002.

Barney Graham is an immunologist, virologist and clinical trials physician, whose primary interests are viral pathogenesis, immunity and vaccine development. His work is focused on HIV, respiratory syncytial virus (RSV) and emerging viral diseases. After graduating from Rice University, Texas, USA, he obtained his M.D. from the University of Kansas School of Medicine, USA. Following a residency, chief residencies and a fellowship in infectious diseases, he completed a Ph.D. in microbiology and immunology at Vanderbilt University School of Medicine, Tennessee, USA, where he subsequently rose to the rank of Professor. In 2000, he became one of the founding investigators for the National Institute of Allergy and Infectious Diseases Vaccine Research Center at the National Institutes of Health, where he is Chief of the Viral Pathogenesis Laboratory and Clinical Trials Core. His laboratory investigates basic mechanisms by which T cells affect viral clearance and immunopathology, and how T cell function can be modulated by vaccination. Vaccine development for RSV and understanding how RSV influences and evades adaptive immunity are projects of particular interest. The clinical trials unit he directs evaluates experimental viral vaccines in Phase I studies, with a primary emphasis on candidate vaccines for HIV, biodefence and emerging infections. He has a special interest in defining development pathways for vaccines against difficult and emerging viral diseases.

Gary Nabel serves as Director of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. He graduated from Harvard College, Massachusetts, USA, before continuing at Harvard, completing his Ph.D., and his M.D. 2 years later. Before his appointment at the VRC, he served as Henry Sewall Professor of Internal Medicine, Professor of Biochemistry and Howard Hughes Medical Institute Investigator at the University of Michigan in Ann Arbor, USA, where he pioneered gene therapy studies for cancer, developed a genetic vaccine for HIV and initiated his research programme to develop Ebola vaccines. As director of the VRC, he provides overall direction and scientific leadership of the basic, clinical and translational research activities of the VRC, and guides VRC development of novel vaccine strategies against HIV and other emerging and re-emerging infectious diseases, including Ebola and Marburg viral haemorrhagic fevers, influenza and chikungunya. Under his leadership, the VRC was able to initiate its first clinical trial, a Phase I study of an HIV/AIDS vaccine, within a year after opening. His laboratory has also developed novel strategies for immunization against Ebola and Marburg, and vaccines against these viruses are currently being tested in Phase I safety trials. Additional vaccine studies will begin soon. In recognition of his expertise at the forefront of virology, immunology, gene therapy and molecular biology, he was elected a member of the Institute of Medicine of the National Academy of Sciences in 1998. He is also an active member in the American Society for Microbiology, as well as a fellow of the American Association for the Advancement of Science.

Related links

FURTHER INFORMATION

Nancy J. Sullivan's homepage

ClinicalTrials.gov

Drug Information from the Centre for Drug Evaluation and Research

FDA Code of Federal Regulations CFR 21 314.600

National Institute of Allergy and Infectious Diseases (Understanding Vaccine Clinical Studies)

Competing interests

N.J.S. and G.J.N. have an intellectual property application related to this subject through the National Institutes of Health.